1,095 results on '"Dreicer, Robert"'
Search Results
102. A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.
103. PrE0807: A phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).
104. Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer (mCRPC).
105. Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer
106. A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma
107. Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease
108. A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer
109. Clinical and Immunomodulatory Effects of Celecoxib Plus Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients with COX-2 Tumor Immunostaining
110. A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer
111. Current status of cytotoxic chemotherapy in patients with metastatic prostate cancer
112. Phase I/II Trial of 5-Fluorouracil and a Noncytotoxic Dose Level of Suramin in Patients with Metastatic Renal Cell Carcinoma
113. Antitumor Effects of Sunitinib or Sorafenib in Patients With Metastatic Renal Cell Carcinoma Who Received Prior Antiangiogenic Therapy
114. Sipuluecel-T immunotherapy for castration-resistant prostate cancer
115. A PHASE 2 TRIAL OF PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATE (PSMA ADC) IN TAXANE-TREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): MP70-20
116. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma
117. Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma
118. Advanced Treatment Strategies in Prostate Cancer: A Closer Look at the Current and Emerging Therapeutic Options.
119. Phase IIb trial of oral ModraDoc006/r as a tolerable and effective option in comparison with intravenous docetaxel in metastatic castration-resistant prostate cancer (mCRPC).
120. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I
121. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel
122. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer
123. Lenalidomide: Immunomodulatory, antiangiogenic, and clinical activity in solid tumors
124. Phase I trial of thalidomide and Interleukin-2 in patients with metastatic renal cell carcinoma
125. Chemotherapy for muscle-invasive bladder cancer in the perioperative setting: Current standards
126. Phase II trial of capecitabine and rHu-interferon-α-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity
127. Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Maintenance Sunitinib Versus Placebo After Chemotherapy for Patients with Advanced Urothelial Carcinoma: Scientific Rationale and Study Design
128. Adjuvant Weekly Docetaxel for Patients With High Risk Prostate Cancer After Radical Prostatectomy: A Multi-Institutional Pilot Study
129. Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors
130. CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors
131. Current Management of Castration-Resistant Prostate Cancer (CRPC)
132. Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: A report from the Bladder Cancer Advocacy Network Clinical Trials Working Group
133. Piritrexim in Advanced, Refractory Carcinoma of the Urothelium (E3896): A Phase II Trial of the Eastern Cooperative Oncology Group
134. Locally advanced and metastatic bladder cancer
135. Locally advanced prostate cancer
136. Systemic therapy for advanced adrenal cancer
137. Phase II Trial of GM-CSF in Advanced Prostate Cancer
138. Contributors
139. Prostate Cancer
140. Tyrosine Kinase Inhibitors Compared with Cytokine Therapy for Metastatic Renal Cell Carcinoma: Overview of Recent Clinical Trials Differentiating Clinical Response and Adverse Effects
141. Cessation of vascular endothelial growth factor–targeted therapy in patients with metastatic renal cell carcinoma: Feasibility and clinical outcome
142. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib
143. Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma
144. Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): Results from a phase I-II clinical trial
145. Phase II Trial of Suramin in Patients with Metastatic Renal Cell Carcinoma
146. Maximizing outcomes in genitourinary cancers across the treatment continuum
147. The Impact of Tumor Burden Characteristics in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
148. Gemcitabine and Docetaxel in Metastatic, Castrate-Resistant Prostate Cancer#: Results From a Phase 2 Trial
149. Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
150. Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.